Leykin I - Search Results

1

Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation.

Koeller KM, Haggarty SJ, Perkins BD, Leykin I, Wong JC, Kao MC, Schreiber SL. Koeller KM, et al. Among authors: leykin i. Chem Biol. 2003 May;10(5):397-410. doi: 10.1016/s1074-5521(03)00093-0. Chem Biol. 2003. PMID: 12770822

2

HumanUpstream and MouseUpstream: databases of promoter sequences in the human and mouse genomes.

Leykin I, Kao MC, Wong WH. Leykin I, et al. OMICS. 2005 Fall;9(3):220-4. doi: 10.1089/omi.2005.9.220. OMICS. 2005. PMID: 16209636

3

Comparative linkage analysis and visualization of high-density oligonucleotide SNP array data.

Leykin I, Hao K, Cheng J, Meyer N, Pollak MR, Smith RJ, Wong WH, Rosenow C, Li C. Leykin I, et al. BMC Genet. 2005 Feb 15;6:7. doi: 10.1186/1471-2156-6-7. BMC Genet. 2005. PMID: 15713228 Free PMC article.

4

Extensive and divergent circadian gene expression in liver and heart.

Storch KF, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, Weitz CJ. Storch KF, et al. Among authors: leykin i. Nature. 2002 May 2;417(6884):78-83. doi: 10.1038/nature744. Epub 2002 Apr 21. Nature. 2002. PMID: 11967526

5

Mitochondrial gene expression and increased oxidative metabolism: role in increased lifespan of fat-specific insulin receptor knock-out mice.

Katic M, Kennedy AR, Leykin I, Norris A, McGettrick A, Gesta S, Russell SJ, Bluher M, Maratos-Flier E, Kahn CR. Katic M, et al. Among authors: leykin i. Aging Cell. 2007 Dec;6(6):827-39. doi: 10.1111/j.1474-9726.2007.00346.x. Aging Cell. 2007. PMID: 18001293 Free PMC article.

6

A point mutation in the amino terminus of TLR7 abolishes signaling without affecting ligand binding.

Iavarone C, Ramsauer K, Kubarenko AV, Debasitis JC, Leykin I, Weber AN, Siggs OM, Beutler B, Zhang P, Otten G, D'Oro U, Valiante NM, Mbow ML, Visintin A. Iavarone C, et al. Among authors: leykin i. J Immunol. 2011 Apr 1;186(7):4213-22. doi: 10.4049/jimmunol.1003585. Epub 2011 Mar 7. J Immunol. 2011. PMID: 21383246

7

Mixed bone marrow chimerism as a treatment for autoimmune diabetes.

Leykin I, Nikolic B, Sykes M. Leykin I, et al. Transplant Proc. 2001 Feb-Mar;33(1-2):120. doi: 10.1016/s0041-1345(00)01935-7. Transplant Proc. 2001. PMID: 11266737 No abstract available.

8

Mixed hematopoietic chimerism allows cure of autoimmune diabetes through allogeneic tolerance and reversal of autoimmunity.

Nikolic B, Takeuchi Y, Leykin I, Fudaba Y, Smith RN, Sykes M. Nikolic B, et al. Among authors: leykin i. Diabetes. 2004 Feb;53(2):376-83. doi: 10.2337/diabetes.53.2.376. Diabetes. 2004. PMID: 14747288

9

Distinct requirements for achievement of allotolerance versus reversal of autoimmunity via nonmyeloablative mixed chimerism induction in NOD mice.

Nikolic B, Onoe T, Takeuchi Y, Khalpey Z, Primo V, Leykin I, Smith RN, Sykes M. Nikolic B, et al. Among authors: leykin i. Transplantation. 2010 Jan 15;89(1):23-32. doi: 10.1097/TP.0b013e3181c4692e. Transplantation. 2010. PMID: 20061915 Free PMC article.

10

Politicized Demography and Biomedical Authority in Post-Soviet Russia.

Leykin I, Rivkin-Fish M. Leykin I, et al. Med Anthropol. 2022 Sep-Oct;41(6-7):702-717. doi: 10.1080/01459740.2021.1987897. Epub 2021 Oct 28. Med Anthropol. 2022. PMID: 34709964

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Search Page

Filters